- Home
- SSP vs CGEN Comparison
SSP vs CGEN Comparison
Compare SSP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- CGEN
- Stock Information
- Founded
- SSP 1878
- CGEN 1993
- Country
- SSP United States
- CGEN Israel
- Employees
- SSP N/A
- CGEN N/A
- Industry
- SSP Broadcasting
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSP Industrials
- CGEN Health Care
- Exchange
- SSP Nasdaq
- CGEN Nasdaq
- Market Cap
- SSP 252.6M
- CGEN 167.4M
- IPO Year
- SSP 1988
- CGEN 2000
- Fundamental
- Price
- SSP $3.32
- CGEN $1.80
- Analyst Decision
- SSP Strong Buy
- CGEN
- Analyst Count
- SSP 1
- CGEN 0
- Target Price
- SSP $8.00
- CGEN N/A
- AVG Volume (30 Days)
- SSP 906.8K
- CGEN 181.3K
- Earning Date
- SSP 08-07-2025
- CGEN 08-05-2025
- Dividend Yield
- SSP N/A
- CGEN N/A
- EPS Growth
- SSP N/A
- CGEN N/A
- EPS
- SSP 0.93
- CGEN N/A
- Revenue
- SSP $2,472,701,000.00
- CGEN $27,589,000.00
- Revenue This Year
- SSP N/A
- CGEN N/A
- Revenue Next Year
- SSP $9.51
- CGEN $173.80
- P/E Ratio
- SSP $3.57
- CGEN N/A
- Revenue Growth
- SSP 6.28
- CGEN N/A
- 52 Week Low
- SSP $1.36
- CGEN $1.13
- 52 Week High
- SSP $4.06
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- SSP 67.71
- CGEN 58.50
- Support Level
- SSP $2.70
- CGEN $1.62
- Resistance Level
- SSP $3.17
- CGEN $1.81
- Average True Range (ATR)
- SSP 0.22
- CGEN 0.08
- MACD
- SSP 0.03
- CGEN -0.00
- Stochastic Oscillator
- SSP 94.74
- CGEN 69.57
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.